EFFETTO DELLA CDP-COLINA SUL DECADIMENTO MENTALE SENILE. ESPERIENZA POLICENTRICA SU 237 CASI

F. Serra; G. P. Diaspri; A. Gasbarrini; S. Giancane; A. Rimondi; M. R. Tame; E. Sakellaridis; M. Bernardi; G. Gasbarrini

EFFETTO DELLA CDP-COLINA SUL DECADIMENTO MENTALE SENILE. ESPERIENZA POLICENTRICA SU 237 CASI

Translated title of the contribution: CDP-choline effect on brain aging. Multicenter experience on 237 patients

F. Serra, G. P. Diaspri, A. Gasbarrini, S. Giancane, A. Rimondi, M. R. Tame, E. Sakellaridis, M. Bernardi, G. Gasbarrini

Istituti Ortopedici Rizzoli

Research output: Contribution to journal › Article › peer-review

Abstract

The efficacy of CDP-choline (1000 mg/die) administered for two-21 day treatment cycles, with a one-week wash-out period between them, was evaluated in out and in-patients suffering from mild to moderate brain aging. The study was performed on 237 fully evaluable patients with the use of the reduced geriatric scale of Plutchik and al., for clinical evaluation of the symptomatology. The clinical data obtained demonstrate that treatment with CDP-choline is able to determine an improvement of symptomatology since the 1st cycle of therapy (p

Translated title of the contribution	CDP-choline effect on brain aging. Multicenter experience on 237 patients
Original language	Italian
Pages (from-to)	465-470
Number of pages	6
Journal	Minerva Medica
Volume	81
Issue number	6
Publication status	Published - 1990

ASJC Scopus subject areas

Medicine(all)

Fingerprint Dive into the research topics of 'CDP-choline effect on brain aging. Multicenter experience on 237 patients'. Together they form a unique fingerprint.

Cite this

@article{a8f1bcf7b52840238a021a818d67c0e6,

title = "EFFETTO DELLA CDP-COLINA SUL DECADIMENTO MENTALE SENILE. ESPERIENZA POLICENTRICA SU 237 CASI",

abstract = "The efficacy of CDP-choline (1000 mg/die) administered for two-21 day treatment cycles, with a one-week wash-out period between them, was evaluated in out and in-patients suffering from mild to moderate brain aging. The study was performed on 237 fully evaluable patients with the use of the reduced geriatric scale of Plutchik and al., for clinical evaluation of the symptomatology. The clinical data obtained demonstrate that treatment with CDP-choline is able to determine an improvement of symptomatology since the 1st cycle of therapy (p",

author = "F. Serra and Diaspri, {G. P.} and A. Gasbarrini and S. Giancane and A. Rimondi and Tame, {M. R.} and E. Sakellaridis and M. Bernardi and G. Gasbarrini",

year = "1990",

language = "Italian",

volume = "81",

pages = "465--470",

journal = "Minerva Medicolegale e Archivio di Antropologia Criminale",

issn = "0026-4806",

publisher = "Edizioni Minerva Medica S.p.A.",

number = "6",

}

TY - JOUR

T1 - EFFETTO DELLA CDP-COLINA SUL DECADIMENTO MENTALE SENILE. ESPERIENZA POLICENTRICA SU 237 CASI

AU - Serra, F.

AU - Diaspri, G. P.

AU - Gasbarrini, A.

AU - Giancane, S.

AU - Rimondi, A.

AU - Tame, M. R.

AU - Sakellaridis, E.

AU - Bernardi, M.

AU - Gasbarrini, G.

PY - 1990

Y1 - 1990

N2 - The efficacy of CDP-choline (1000 mg/die) administered for two-21 day treatment cycles, with a one-week wash-out period between them, was evaluated in out and in-patients suffering from mild to moderate brain aging. The study was performed on 237 fully evaluable patients with the use of the reduced geriatric scale of Plutchik and al., for clinical evaluation of the symptomatology. The clinical data obtained demonstrate that treatment with CDP-choline is able to determine an improvement of symptomatology since the 1st cycle of therapy (p

AB - The efficacy of CDP-choline (1000 mg/die) administered for two-21 day treatment cycles, with a one-week wash-out period between them, was evaluated in out and in-patients suffering from mild to moderate brain aging. The study was performed on 237 fully evaluable patients with the use of the reduced geriatric scale of Plutchik and al., for clinical evaluation of the symptomatology. The clinical data obtained demonstrate that treatment with CDP-choline is able to determine an improvement of symptomatology since the 1st cycle of therapy (p

UR - http://www.scopus.com/inward/record.url?scp=0025003593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025003593&partnerID=8YFLogxK

M3 - Articolo

C2 - 2193245

AN - SCOPUS:0025003593

VL - 81

SP - 465

EP - 470

JO - Minerva Medicolegale e Archivio di Antropologia Criminale

JF - Minerva Medicolegale e Archivio di Antropologia Criminale

SN - 0026-4806

IS - 6

ER -